Clinical Trial Update: Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC [Phase 3]

View source ↗

Summary

This Phase 3 trial investigates durvalumab and tremelimumab with or without lenvatinib in combination with transarterial chemoembolization for locoregional hepa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• IMFINZI (DURVALUMAB)
• LENVIMA (lenvatinib)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: AstraZeneca | Conditions: Hepatocellular Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING